metformiinilla
Metformiinilla is the Finnish designation for metformin, a widely prescribed oral antidiabetic medication in the biguanide class. It is used to improve glycemic control in adults with type 2 diabetes and is also employed in certain cases of polycystic ovary syndrome (PCOS) and gestational diabetes under medical guidance. Metformiinilla is typically part of a broader treatment plan that includes diet and exercise, and it is often chosen as a first-line therapy because it lowers blood glucose without causing hypoglycemia when used alone.
The primary mechanism of action involves reducing hepatic glucose production and increasing insulin sensitivity in peripheral
Indications for metformin include initial pharmacological management of type 2 diabetes in adults, with potential use
Dosing commonly starts at 500 mg once daily with meals, with gradual titration to 1500–2000 mg per
Common adverse effects are gastrointestinal, such as nausea, diarrhea, and abdominal discomfort, usually transient. Long-term use